Donald N. Buell

11.1k total citations · 2 hit papers
73 papers, 7.2k citations indexed

About

Donald N. Buell is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Donald N. Buell has authored 73 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Infectious Diseases, 22 papers in Epidemiology and 14 papers in Molecular Biology. Recurrent topics in Donald N. Buell's work include Antifungal resistance and susceptibility (36 papers), Fungal Infections and Studies (15 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Donald N. Buell is often cited by papers focused on Antifungal resistance and susceptibility (36 papers), Fungal Infections and Studies (15 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Donald N. Buell collaborates with scholars based in United States, Japan and United Kingdom. Donald N. Buell's co-authors include Jesse Roth, James R. Gavin, Thomas J. Walsh, Ihor Bekersky, Pierre De Meyts, David M. Neville, James J. Keirns, John L. Fahey, Robert M. Fielding and Laura Kovanda and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Donald N. Buell

71 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin-Dependent Regulation of Insulin Receptor Concentrations: A Direct Demonstration in Cell Culture

1974 866 citations James R. Gavin, Jesse Roth et al. Proceedings of the National Academy of Sciences profile →
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis

2007 478 citations Peter G. Pappas, Robert F. Betts et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donald N. Buell United States	43	3.7k	2.9k	1.3k	878	866	73	7.2k
Gerald L. Mandell United States	41	1.7k 0.5×	1.5k 0.5×	1.2k 0.9×	499 0.6×	691 0.8×	129	6.0k
Marc Rubin United States	33	2.6k 0.7×	2.2k 0.8×	1.3k 1.0×	2.1k 2.4×	464 0.5×	52	8.1k
Johan R. Boelaert Belgium	44	2.2k 0.6×	1.4k 0.5×	977 0.7×	339 0.4×	485 0.6×	141	5.8k
Adilia Warris Netherlands	41	3.6k 1.0×	3.0k 1.0×	717 0.5×	488 0.6×	393 0.5×	169	5.8k
R. van Furth Netherlands	55	1.6k 0.4×	2.3k 0.8×	2.5k 1.9×	1.0k 1.2×	455 0.5×	284	11.6k
Brahm H. Segal United States	55	6.7k 1.8×	5.9k 2.0×	1.9k 1.4×	1.5k 1.7×	653 0.8×	162	12.7k
Andreas Schaffner Switzerland	36	1.5k 0.4×	1.5k 0.5×	726 0.5×	415 0.5×	136 0.2×	95	5.0k
Elio Cenci Italy	43	3.2k 0.9×	2.7k 1.0×	652 0.5×	442 0.5×	193 0.2×	116	5.8k
Paul Deutsch United States	38	4.5k 1.2×	1.4k 0.5×	1.9k 1.4×	631 0.7×	472 0.5×	64	8.6k
Edward D. Chan United States	55	2.7k 0.7×	3.3k 1.1×	1.9k 1.4×	765 0.9×	196 0.2×	210	8.6k

Countries citing papers authored by Donald N. Buell

Since Specialization

Citations

This map shows the geographic impact of Donald N. Buell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald N. Buell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald N. Buell more than expected).

Fields of papers citing papers by Donald N. Buell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald N. Buell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald N. Buell. The network helps show where Donald N. Buell may publish in the future.

Co-authorship network of co-authors of Donald N. Buell

This figure shows the co-authorship network connecting the top 25 collaborators of Donald N. Buell. A scholar is included among the top collaborators of Donald N. Buell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald N. Buell. Donald N. Buell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kontoyiannis, Dimitrios P., V. Ratanatharathorn, Jo‐Anne H. Young, et al.. (2008). Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease. 11(1). 89–93. 75 indexed citations

Pappas, Peter G., Robert F. Betts, Márcio Nucci, et al.. (2007). Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clinical Infectious Diseases. 45(7). 883–893. 478 indexed citations breakdown →

Denning, David W., Kieren A. Marr, W. Lau, et al.. (2006). Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. Journal of Infection. 53(5). 337–349. 209 indexed citations

Hébert, Mary F., Robert Townsend, Stephen M. Austin, et al.. (2005). Concomitant Cyclosporine and Micafungin Pharmacokinetics in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(8). 954–960. 83 indexed citations

Hiemenz, J., Pablo J. Cagnoni, David Simpson, et al.. (2005). Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant. Antimicrobial Agents and Chemotherapy. 49(4). 1331–1336. 122 indexed citations

Hébert, Mary F., Helen Smith, Thomas Marbury, et al.. (2005). Pharmacokinetics of Micafungin in Healthy Volunteers, Volunteers With Moderate Liver Disease, and Volunteers With Renal Dysfunction. The Journal of Clinical Pharmacology. 45(10). 1145–1152. 136 indexed citations

Bekersky, Ihor, et al.. (2001). Pharmacokinetics, Excretion, and Mass Balance of ¹⁴C after Administration of ¹⁴C‐Cholesterol‐Labeled AmBisome to Healthy Volunteers. The Journal of Clinical Pharmacology. 41(9). 963–971.

Bekersky, I, Robert M. Fielding, Dawna Dressler, et al.. (2001). Pharmacokinetics, Excretion, and Mass Balance of <SUP>14</SUP>C after Administration of <SUP>14</SUP>C-Cholesterol-Labeled AmBisome to Healthy Volunteers. The Journal of Clinical Pharmacology. 41(9). 963–971. 27 indexed citations

Nash, Richard A., Joseph H. Antin, Chatchada Karanes, et al.. (2000). Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.. PubMed. 96(6). 2062–8. 426 indexed citations

10.

Walsh, Thomas J., Vijay Yeldandi, Maureen McEvoy, et al.. (1998). Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients. Antimicrobial Agents and Chemotherapy. 42(9). 2391–2398. 139 indexed citations

11.

Lake, Diana, et al.. (1996). Fluconazole versus Amphotericin B in the Treatment of Esophageal Candidiasis in Cancer Patients. Chemotherapy. 42(4). 308–314. 28 indexed citations

12.

Winston, Drew J., Pranatharthi Chandrasekar, Hillard M. Lazarus, et al.. (1993). Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial. Annals of Internal Medicine. 118(7). 495–503. 312 indexed citations

13.

Jaffe, N, et al.. (1977). Role of staging in childhood non-Hodgkin's lymphoma.. PubMed. 61(6). 1001–7. 11 indexed citations

14.

Ebert, Paul S., et al.. (1976). Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 36(5). 1809–13. 69 indexed citations

15.

Isersky, Chaviva, H Metzger, & Donald N. Buell. (1975). Cell cycle-associated changes in receptors for IgE during growth and differentiation of a rat basophilic leukemia cell line.. The Journal of Experimental Medicine. 141(5). 1147–1162. 50 indexed citations

16.

Andrews, Alan D., Jay H. Robbins, Kenneth H. Kraemer, & Donald N. Buell. (1974). Brief Communication: Xeroderma Pigmentosum Long-Term Lymphoid Lines With Increased Ultraviolet Sensitivity. JNCI Journal of the National Cancer Institute. 53(3). 691–693. 35 indexed citations

17.

Gavin, James R., Jesse Roth, David M. Neville, Pierre De Meyts, & Donald N. Buell. (1974). Insulin-Dependent Regulation of Insulin Receptor Concentrations: A Direct Demonstration in Cell Culture. Proceedings of the National Academy of Sciences. 71(1). 84–88. 866 indexed citations breakdown →

18.

Everson, Lloyd K., Donald N. Buell, & G. Nicholas Rogentine. (1973). SEPARATION OF HUMAN LYMPHOID CELLS INTO G1, S, AND G2 CELL CYCLE POPULATIONS BY USE OF A VELOCITY SEDIMENTATION TECHNIQUE. The Journal of Experimental Medicine. 137(2). 343–358. 22 indexed citations

19.

Allansmith, Mathea & Donald N. Buell. (1965). Immunoglobulins in the Skin of Allergic and Nonallergic Individuals. The Journal of Immunology. 95(5). 951–958. 7 indexed citations

20.

Allansmith, Mathea, Donald N. Buell, & C. James McKnight. (1964). Serum Electrophoretic Patterns in Vernal Conjunctivitis. American Journal of Ophthalmology. 57(3). 400–402. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact